Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]

Related Keywords

United States ,American ,Leerink Partnrs ,Timothya Springer ,Hall Laurie ,Sg Americas Securities ,American International Group Inc ,Securities Exchange Commission ,Delphi Financial Group Inc ,Cartesian Therapeutics Inc ,Cartesian Therapeutics Company Profile ,Needham Company ,Cartesian Therapeutics ,Free Report ,Therapeutics Trading Down ,Get Free Report ,Director Timothy ,Exchange Commission ,Lauriej Trustee ,International Group ,Financial Markets ,Delphi Financial Group ,Cartesian Therapeutics Daily ,